October 14, 2015 | Israeli bio-medical company Meditemp has signed a non-binding Letter of Intent with Generex Biotechnology, which according to the letter, could acquire a 51% equity interest in MediTemp in exchange for a purchase price of $5 million. Founded in 2007, MediTemp has developed a proprietary cooling technology designed to improve sperm quality in men rendered infertile due to varicoceles, a condition characterized by enlarged veins (varicose) within the scrotum. The company’s solution is called Varicure, a wearable, compact, portable and comfortable device that facilitates localized cooling of the testicles with the aim of enhancing male fertility by improving sperm quality.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023

Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023

Israel, UK Ink Deal For Greater Innovation Collaboration
September 21, 2023

ALS Drug Receives Patent In Israel, Europe, Japan
September 20, 2023
Facebook comments